Cargando…
Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
Uterine leiomyosarcoma (LMS) is a rare malignant neoplasm of the female genital tract poorly responsive to conventional chemotherapy and radiotherapy, with an overall poor prognosis. Pazopanib is at the moment the only FDA-approved targeted molecular therapy for uterine LMS, given the exceedingly ra...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255722/ https://www.ncbi.nlm.nih.gov/pubmed/34248545 http://dx.doi.org/10.1159/000516758 |
_version_ | 1783717966167146496 |
---|---|
author | Testa, Stefano Million, Lynn Longacre, Teri Bui, Nam |
author_facet | Testa, Stefano Million, Lynn Longacre, Teri Bui, Nam |
author_sort | Testa, Stefano |
collection | PubMed |
description | Uterine leiomyosarcoma (LMS) is a rare malignant neoplasm of the female genital tract poorly responsive to conventional chemotherapy and radiotherapy, with an overall poor prognosis. Pazopanib is at the moment the only FDA-approved targeted molecular therapy for uterine LMS, given the exceedingly rare occurrence of actionable genetic mutations in this type of cancer. Here, we describe the first reported case of metastatic uterine LMS with an FN1-anaplastic lymphoma kinase (ALK) fusion mutation occurring in a 63-year-old woman with a history of uterine leiomyomas. The patient progressed on several lines of therapy, including conventional chemotherapy, pazopanib, and the first-generation ALK inhibitor crizotinib. Interestingly, the patient showed a remarkable 16-month response to second generation ALK inhibitors alectinib and lorlatinib. This case demonstrates that ALK inhibitors can be an effective therapeutic strategy for patients with ALK fusion-positive uterine LMS that has progressed on conventional chemotherapy. |
format | Online Article Text |
id | pubmed-8255722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-82557222021-07-09 Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib Testa, Stefano Million, Lynn Longacre, Teri Bui, Nam Case Rep Oncol Case Report Uterine leiomyosarcoma (LMS) is a rare malignant neoplasm of the female genital tract poorly responsive to conventional chemotherapy and radiotherapy, with an overall poor prognosis. Pazopanib is at the moment the only FDA-approved targeted molecular therapy for uterine LMS, given the exceedingly rare occurrence of actionable genetic mutations in this type of cancer. Here, we describe the first reported case of metastatic uterine LMS with an FN1-anaplastic lymphoma kinase (ALK) fusion mutation occurring in a 63-year-old woman with a history of uterine leiomyomas. The patient progressed on several lines of therapy, including conventional chemotherapy, pazopanib, and the first-generation ALK inhibitor crizotinib. Interestingly, the patient showed a remarkable 16-month response to second generation ALK inhibitors alectinib and lorlatinib. This case demonstrates that ALK inhibitors can be an effective therapeutic strategy for patients with ALK fusion-positive uterine LMS that has progressed on conventional chemotherapy. S. Karger AG 2021-06-11 /pmc/articles/PMC8255722/ /pubmed/34248545 http://dx.doi.org/10.1159/000516758 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Testa, Stefano Million, Lynn Longacre, Teri Bui, Nam Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib |
title | Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib |
title_full | Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib |
title_fullStr | Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib |
title_full_unstemmed | Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib |
title_short | Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib |
title_sort | uterine leiomyosarcoma with fn1-anaplastic lymphoma kinase fusion responsive to alectinib and lorlatinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255722/ https://www.ncbi.nlm.nih.gov/pubmed/34248545 http://dx.doi.org/10.1159/000516758 |
work_keys_str_mv | AT testastefano uterineleiomyosarcomawithfn1anaplasticlymphomakinasefusionresponsivetoalectinibandlorlatinib AT millionlynn uterineleiomyosarcomawithfn1anaplasticlymphomakinasefusionresponsivetoalectinibandlorlatinib AT longacreteri uterineleiomyosarcomawithfn1anaplasticlymphomakinasefusionresponsivetoalectinibandlorlatinib AT buinam uterineleiomyosarcomawithfn1anaplasticlymphomakinasefusionresponsivetoalectinibandlorlatinib |